Yuchao Sun

Yuchao Sun

Auto-generated profile, based on publicly available information

Yuchao Sun

The Core Facilities The Fourth Afliated Hospital of School of Medicine and International School of Medicine International Institutes of Medicine Zhejiang University Yiwu 322000 China zju.edu.cn

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2023 in International Reviews of Immunology
Verified
Journal Article
Closed access
LLLele Li
Lele Li
XXxiaoping xia
xiaoping xia
TYTian Yang
Tian Yang
YSYuchao Sun
Yuchao Sun
XLXueke Liu
Xueke Liu
YWyingping wu
yingping wu
Autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) are caused by the body's immune response to autoantigens. The pathogenesis of autoimmune diseases is unclear. Numerous studies have demonstrated that RNA methylation plays a key role in disease progression, which is essential for post-transcriptional regulation and has gradually become a broad regulatory mechanism that controls gene expression in various physiological processes, including RNA nuclear output, translation, splicing, and noncoding RNA processing. Here, we outline the writers, erasers, and readers of RNA methylation, including N6-methyladenosine (m6A), 2'-O-methylation (Nm), 2'-O-dimethyladenosine (m6Am), N1-methyladenosine (m1A), 5-methylcytidine (m5C) and N7-methylguanosine (m7G). As the role of RNA methylation modifications in the immune system and diseases is explained, the potential treatment value of these modifications has also been demonstrated. This review reports the relationship between RNA methylation and autoimmune diseases, highlighting the need for future research into the therapeutic potential of RNA modifications.

23 December 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LZLijun Zheng
Lijun Zheng
HZHui Zhang
Hui Zhang
YSYuchao Sun
Yuchao Sun
Acute kidney injury (AKI) is a critical clinical syndrome with limited therapeutic options. This study investigated the renoprotective effects of lycopene, a potent antioxidant, in both in vivo and in vitro AKI models. In a murine cecal ligation and puncture (CLP)-induced sepsis-AKI model, pretreatment with lycopene (10, 20, 40 mg/kg) dose-dependently ameliorated renal histopathological damage (HE staining) and restored serum biomarkers (AST, ALT, BUN, CREA). Mechanistically, lycopene suppressed oxidative stress and apoptosis by downregulating the PI3K/Akt axis: it significantly reversed the CLP-induced upregulating of p-PI3K and p-Akt, and the pro-apoptotic proteins (Bax, Cleaved Caspase-3), while increasing Nrf 2 and SOD1. Consistent results were observed in LPS- and H₂O₂-induced cellular AKI models, where lycopene attenuated cell death and restored redox homeostasis in a dose-dependent manner. Immunofluorescence assays further validated these trends. Crucially, PI3K siRNA or cDNA transfection experiments confirmed that lycopene’s antioxidant and anti-apoptotic effects were PI3K-dependent. Our findings highlight lycopene as a promising therapeutic agent for AKI, acting via PI3K/Akt-mediated activation of Nrf 2 to counteract oxidative damage and apoptosis. This study provides novel insights into the molecular mechanisms underlying lycopene’s renoprotection and supports its potential clinical translation for sepsis or oxidative stress-associated AKI.

1 January 2025 in Journal of Food Biochemistry
Verified
Journal Article
Open access
LLLi Li
Li Li
YWYanyan Wang
Yanyan Wang
YSYuchao Sun
Yuchao Sun
Background: Hepatic ischemia‐reperfusion injury (HIRI) is a critical clinical challenge, and lycopene, a natural carotenoid with antioxidant properties, has shown potential in mitigating organ damage. This research evaluated the therapeutic potential and mechanistic basis of lycopene against HIRI utilizing in vivo and in vitro approaches. Methods: A rat HIRI model and AML‐12 cell models (H 2 O 2 ‐induced oxidative stress and hypoxia/reoxygenation [H/R]) were established. Results: Lycopene significantly alleviated HIRI in rats, evidenced by improved hepatic histopathology (HE staining), restored antioxidant enzyme activities (SOD1 and GSH), and reduced proinflammatory cytokines (TNF‐α, IL‐6, and IL‐1β). Notably, HRD1, an E3 ubiquitin ligase, exhibited dynamic temporal expression: In mild HIRI (30 min ischemia/6 h reperfusion), HRD1 initially increased adaptively but declined thereafter, whereas severe ischemia (60 min) caused persistent HRD1 upregulation during reperfusion, exacerbating apoptosis and liver dysfunction. Lycopene treatment normalized HRD1 levels, reducing apoptosis markers (Bax, Cleaved‐Caspase‐3) and enhancing antiapoptotic Bcl‐2. In vitro, lycopene attenuated H 2 O 2 ‐ and H/R‐induced oxidative stress, inflammation, and apoptosis. Mechanistically, genetic manipulation of HRD1 (silencing or overexpression) confirmed that it targets Nrf2, the central regulator of antioxidant defense, for degradation. Lycopene suppressed HRD1‐mediated Nrf2 ubiquitination, thereby stabilizing Nrf2 and activating downstream antioxidant genes (HO‐1 and NQO1). Conclusions: These findings demonstrate that lycopene ameliorates HIRI by modulating the HRD1‐Nrf2 axis, highlighting its therapeutic potential via dual antioxidant and antiapoptotic mechanisms. This study provides novel insights into HRD1’s context‐dependent roles in HIRI and positions lycopene as a promising candidate for clinical translation.

1 January 2026 in Journal of Food Biochemistry
Verified
Journal Article
Open access
PDF file
ZCZhiming Cui
Zhiming Cui
YWYanyan Wang
Yanyan Wang
JLJiaying Liu
Jiaying Liu
NLNa Li
Na Li
JHJibo Hu
Jibo Hu
YSYuchao Sun
Yuchao Sun
The development of radiation‐induced lung injury (RILI) presents a major clinical challenge that limits the efficacy and safety of thoracic radiotherapy. This condition evolves from acute inflammatory damage to irreversible fibrotic remodeling, yet effective and targeted treatment options remain scarce. Lycopene, a potent dietary carotenoid predominantly found in tomatoes, possesses a multifaceted pharmacological profile encompassing antioxidant, anti‐inflammatory, and antifibrotic effects. The nebulized delivery of lycopene offers a direct route to the lungs, enhancing site‐specific action and reducing off‐target risks, which addresses a key need in managing RILI. This study explored the protective efficacy and mechanisms of nebulized lycopene in RILI. C57BL/6 mice subjected to 20 Gy thoracic irradiation received lycopene via nebulization as preventive and continuous treatment. BEAS‐2B and NIH‐3T3 cells were treated with irradiation and lycopene in combination with pharmacological inhibitors (ML385 and SB431542) or specific gene knockdown (siNrf2 and siTGF‐β1) to validate pathway dependency. Lung injury, inflammation, fibrosis, oxidative stress, and protein expression were detected by histology, ELISA, Western blot, immunofluorescence, and ROS detection. Lycopene dose‐dependently improved RILI mice’s survival, alleviated lung damage, inhibited inflammation at 4 weeks and fibrosis at 12 weeks, activated the Nrf2/Heme Oxygenase‐1 (HO‐1) pathway in BEAS‐2B cells, and suppressed the TGF‐β1/Smad pathway in NIH‐3T3 cells, with good safety. These findings suggest that nebulized lycopene attenuates RILI through differential modulation of epithelial Nrf2/HO‐1 signaling and fibroblast TGF‐β1/Smad signaling, supporting its candidacy as a dietary bioactive compound for radioprotection.